MICROBE ModulatIng Cancer therapy RespOnse using Bacterial Extracellular nanovesicles

Summary

Our bodies are home to trillions of bacteria. Emerging evidence from patients and mouse models indicates that the host-bacteria interplay determines the development and course of infectious diseases, chronic diseases such as inflammatory bowel disease, as well as the response of tumors to therapy. I hypothesize that bacteria direct this interplay by, among other means, various messenger substances packed in nanometer-sized particles (also called vesicles) that they release. Although this phenomenon has been described long ago, its biological significance in the host-bacteria interplay during the disease course of patients remains largely unknown. Recently, my research group pioneered the discovery of gut-derived immunomodulatory bacterial vesicles in the systemic circulation of non-septicemic patients, including cancer patients. The overall scientific objective of this ERC-CoG project is to map bacterial vesicles in body fluids and investigate how they influence the disease course of patients. These insights can contribute to the development of diagnostic or therapeutic applications.

Results, demos, etc. Show all and search (0)

Unfold all

Fold all

More information & hyperlinks

Web resources:	https://cordis.europa.eu/project/id/101045156
Start date:	01-11-2022
End date:	31-10-2027
Total budget - Public funding:	2 000 000,00 Euro - 2 000 000,00 Euro

Cordis data

Original description

Emerging evidence from cancer patients and mouse models indicates that gut bacteria affect response to immune checkpoint inhibitors (ICI). As a result, modification of gut bacteria by dietary changes, probiotics and fecal transplantations are explored but a huge gap remains to gain clinical application. Limiting factors are the lack of mechanistic knowledge on how gut bacteria impact ICI response, the need of antibiotics to treat infections in cancer patients and gut resilience to exogenous bacterial colonization. Bacteria release nanometer-sized extracellular vesicles (BEV), loaded with specific pathogen-associated molecular patterns (PAMP), which possess multiple favorable characteristics for clinical application but remain minimally explored in oncology. Recently, my research group pioneered the discovery of gut-derived immunomodulatory BEV in the systemic circulation (sysBEV) of non-septicemic cancer patients. I hypothesize that sysBEV direct ICI response by initiating cytokine release to instruct innate and adaptive anti-tumor immunity. The overall scientific objective of my ERC-CoG project is to establish an innovative nanotherapeutic strategy using non-replicating BEV nanoparticles as a game changer to establish a safe but potent and durable ICI response. Hereto, MICROBE will analyze cancer patient biospecimens to address a number of fundamental questions with regard to BEV characteristics that are essential to ICI response and implement this know-how to formulate BEV nanotherapeutics from gut bacteria of healthy donors and ICI responsive cancer patients. The optimal administration route, treatment dosage, pharmaco-kinetics and -dynamics will be established and the synergism between BEV nanotherapeutics and ICI will be elucidated using clinically relevant mouse models. In conclusion, MICROBE will provide the EU a frontrunner position for a future first-in-human clinical trial using BEV nanotherapeutics in anti-cancer treatment.